Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?
Injectable nanosized carriers (5–250nm) are actively studied as anticancer drug delivery agents for targeted drug delivery to the brain. Among these, polymeric nanoparticles (Np) have been studied since 1995, but only five of them recently started Phase I clinical trials, and none of these targets b...
Gespeichert in:
| Veröffentlicht in: | Drug discovery today 2012-04, Vol.17 (7-8), p.367-378 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 378 |
|---|---|
| container_issue | 7-8 |
| container_start_page | 367 |
| container_title | Drug discovery today |
| container_volume | 17 |
| creator | Costantino, Luca Boraschi, Diana |
| description | Injectable nanosized carriers (5–250nm) are actively studied as anticancer drug delivery agents for targeted drug delivery to the brain. Among these, polymeric nanoparticles (Np) have been studied since 1995, but only five of them recently started Phase I clinical trials, and none of these targets brain pathologies. To date, clinical trials for brain drug delivery have started for macromolecular- and nanocarrier-based systems in the treatment of brain tumors. This review, on the basis of the results obtained so far from preclinical studies, will critically consider the possibilities that polymeric Np have to reach the clinic as drug delivery agents for the brain, in comparison with other platforms. |
| doi_str_mv | 10.1016/j.drudis.2011.10.028 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_963827599</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S135964461100393X</els_id><sourcerecordid>963827599</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-8db89927e24807f5e84bbb7e51ebdc47d3176831121af5fb375e659cb90970683</originalsourceid><addsrcrecordid>eNp9kEtvGyEURlHUKknd_IOqYhNlNS4wMMCmURT1EclSNukaAXPHwRozLjCW_O-DZTfLbgB9nPvQQegLJUtKaPdts-zT3Ie8ZITSGi0JUxfomiqpGqFa9qG-W6GbjvPuCn3KeUMIZVp0l-iKMaI54901Mk8Zl1dIgC32Y4jB2xEPc5lrMkwJ76bxsIUUPI42TjubSvAjZGwzdsmG2BSb1lBCXOO6Tj1gDHtIB2zXEEu-_4w-DnbMcHO-F-jPzx8vj7-b1fOvp8eHVeNbTUujeqe0ZhIYV0QOAhR3zkkQFFzvuexbKjvVUsqoHcTgWimgE9o7TbQk9WeB7k59d2n6O0MuZhuyh3G0EaY5G921ikmhdSX5ifRpyjnBYHYpbG06GErM0azZmJNZczR7TKvZWvb1PGB2W-jfi_6prMDtGbC5ShySjb72eOeE1IRpXrnvJw6qjn2AZLIPED30IYEvpp_C_zd5AzSLmVs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>963827599</pqid></control><display><type>article</type><title>Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Costantino, Luca ; Boraschi, Diana</creator><creatorcontrib>Costantino, Luca ; Boraschi, Diana</creatorcontrib><description>Injectable nanosized carriers (5–250nm) are actively studied as anticancer drug delivery agents for targeted drug delivery to the brain. Among these, polymeric nanoparticles (Np) have been studied since 1995, but only five of them recently started Phase I clinical trials, and none of these targets brain pathologies. To date, clinical trials for brain drug delivery have started for macromolecular- and nanocarrier-based systems in the treatment of brain tumors. This review, on the basis of the results obtained so far from preclinical studies, will critically consider the possibilities that polymeric Np have to reach the clinic as drug delivery agents for the brain, in comparison with other platforms.</description><identifier>ISSN: 1359-6446</identifier><identifier>EISSN: 1878-5832</identifier><identifier>DOI: 10.1016/j.drudis.2011.10.028</identifier><identifier>PMID: 22094246</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Animals ; Biological and medical sciences ; Brain - drug effects ; Brain - metabolism ; Clinical Trials as Topic ; Drug Carriers - administration & dosage ; Drug Delivery Systems - methods ; General pharmacology ; Humans ; Medical sciences ; Nanoparticles - administration & dosage ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Polymers - administration & dosage ; Polymers - pharmacokinetics</subject><ispartof>Drug discovery today, 2012-04, Vol.17 (7-8), p.367-378</ispartof><rights>2011 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-8db89927e24807f5e84bbb7e51ebdc47d3176831121af5fb375e659cb90970683</citedby><cites>FETCH-LOGICAL-c391t-8db89927e24807f5e84bbb7e51ebdc47d3176831121af5fb375e659cb90970683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.drudis.2011.10.028$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25790294$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22094246$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Costantino, Luca</creatorcontrib><creatorcontrib>Boraschi, Diana</creatorcontrib><title>Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?</title><title>Drug discovery today</title><addtitle>Drug Discov Today</addtitle><description>Injectable nanosized carriers (5–250nm) are actively studied as anticancer drug delivery agents for targeted drug delivery to the brain. Among these, polymeric nanoparticles (Np) have been studied since 1995, but only five of them recently started Phase I clinical trials, and none of these targets brain pathologies. To date, clinical trials for brain drug delivery have started for macromolecular- and nanocarrier-based systems in the treatment of brain tumors. This review, on the basis of the results obtained so far from preclinical studies, will critically consider the possibilities that polymeric Np have to reach the clinic as drug delivery agents for the brain, in comparison with other platforms.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Clinical Trials as Topic</subject><subject>Drug Carriers - administration & dosage</subject><subject>Drug Delivery Systems - methods</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Nanoparticles - administration & dosage</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymers - administration & dosage</subject><subject>Polymers - pharmacokinetics</subject><issn>1359-6446</issn><issn>1878-5832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtvGyEURlHUKknd_IOqYhNlNS4wMMCmURT1EclSNukaAXPHwRozLjCW_O-DZTfLbgB9nPvQQegLJUtKaPdts-zT3Ie8ZITSGi0JUxfomiqpGqFa9qG-W6GbjvPuCn3KeUMIZVp0l-iKMaI54901Mk8Zl1dIgC32Y4jB2xEPc5lrMkwJ76bxsIUUPI42TjubSvAjZGwzdsmG2BSb1lBCXOO6Tj1gDHtIB2zXEEu-_4w-DnbMcHO-F-jPzx8vj7-b1fOvp8eHVeNbTUujeqe0ZhIYV0QOAhR3zkkQFFzvuexbKjvVUsqoHcTgWimgE9o7TbQk9WeB7k59d2n6O0MuZhuyh3G0EaY5G921ikmhdSX5ifRpyjnBYHYpbG06GErM0azZmJNZczR7TKvZWvb1PGB2W-jfi_6prMDtGbC5ShySjb72eOeE1IRpXrnvJw6qjn2AZLIPED30IYEvpp_C_zd5AzSLmVs</recordid><startdate>20120401</startdate><enddate>20120401</enddate><creator>Costantino, Luca</creator><creator>Boraschi, Diana</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120401</creationdate><title>Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?</title><author>Costantino, Luca ; Boraschi, Diana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-8db89927e24807f5e84bbb7e51ebdc47d3176831121af5fb375e659cb90970683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Clinical Trials as Topic</topic><topic>Drug Carriers - administration & dosage</topic><topic>Drug Delivery Systems - methods</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Nanoparticles - administration & dosage</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymers - administration & dosage</topic><topic>Polymers - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Costantino, Luca</creatorcontrib><creatorcontrib>Boraschi, Diana</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Costantino, Luca</au><au>Boraschi, Diana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?</atitle><jtitle>Drug discovery today</jtitle><addtitle>Drug Discov Today</addtitle><date>2012-04-01</date><risdate>2012</risdate><volume>17</volume><issue>7-8</issue><spage>367</spage><epage>378</epage><pages>367-378</pages><issn>1359-6446</issn><eissn>1878-5832</eissn><abstract>Injectable nanosized carriers (5–250nm) are actively studied as anticancer drug delivery agents for targeted drug delivery to the brain. Among these, polymeric nanoparticles (Np) have been studied since 1995, but only five of them recently started Phase I clinical trials, and none of these targets brain pathologies. To date, clinical trials for brain drug delivery have started for macromolecular- and nanocarrier-based systems in the treatment of brain tumors. This review, on the basis of the results obtained so far from preclinical studies, will critically consider the possibilities that polymeric Np have to reach the clinic as drug delivery agents for the brain, in comparison with other platforms.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>22094246</pmid><doi>10.1016/j.drudis.2011.10.028</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6446 |
| ispartof | Drug discovery today, 2012-04, Vol.17 (7-8), p.367-378 |
| issn | 1359-6446 1878-5832 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_963827599 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Biological and medical sciences Brain - drug effects Brain - metabolism Clinical Trials as Topic Drug Carriers - administration & dosage Drug Delivery Systems - methods General pharmacology Humans Medical sciences Nanoparticles - administration & dosage Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Polymers - administration & dosage Polymers - pharmacokinetics |
| title | Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T22%3A18%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20there%20a%20clinical%20future%20for%20polymeric%20nanoparticles%20as%20brain-targeting%20drug%20delivery%20agents?&rft.jtitle=Drug%20discovery%20today&rft.au=Costantino,%20Luca&rft.date=2012-04-01&rft.volume=17&rft.issue=7-8&rft.spage=367&rft.epage=378&rft.pages=367-378&rft.issn=1359-6446&rft.eissn=1878-5832&rft_id=info:doi/10.1016/j.drudis.2011.10.028&rft_dat=%3Cproquest_cross%3E963827599%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=963827599&rft_id=info:pmid/22094246&rft_els_id=S135964461100393X&rfr_iscdi=true |